Hydroxymethylnitrofurazone (NFOH) decreases parasitaemia, parasitism and tissue lesion caused by infection with the Bolivia Trypanosoma cruzi type I strain in Swiss and C57BL/6 mice
dc.contributor.author | Scarim, Cauê Benito [UNESP] | |
dc.contributor.author | de Andrade, Cleverton Roberto [UNESP] | |
dc.contributor.author | Falcone, Rossana [UNESP] | |
dc.contributor.author | Ambrozini, Letícia Moreno [UNESP] | |
dc.contributor.author | Senhorelli, Vitor Izidoro [UNESP] | |
dc.contributor.author | da Rosa, João Aristeu [UNESP] | |
dc.contributor.author | Chin, Chung Man [UNESP] | |
dc.contributor.institution | Universidade Estadual Paulista (UNESP) | |
dc.date.accessioned | 2023-07-29T16:02:34Z | |
dc.date.available | 2023-07-29T16:02:34Z | |
dc.date.issued | 2022-01-01 | |
dc.description.abstract | The chemical hydroxymethylation of the antimicrobial nitrofurazone leads to the prodrug NFOH, also increases the anti-T. cruzi activities (in vitro and in vivo), as well as showed non-genotoxic (Ames and micronucleus assays). In the present study, we assessed the anti-T. cruzi effect of the NFOH In vivo-in acute Swiss and C57Bl/6 experimental Chagas models. The treatment started at 5 days post-infection during 20 consecutive days (orally, once day, 150mg/kg), and the parasitaemia as well as histopathology analysis were performed. In both experimental murine models, NFOH was able to reduce parasitemia blood avoiding parasitic reactivation, during immunosuppression period (dexamethasone 5mg/kg, 14 days), in 100% of the mice, and decrease tissue parasite nests, demonstrating absence of amastigote forms in all organs (100%) analyzed, data similar to benznidazole (BZN). Therefore, the results shown here pointing to the NFOH as promising compound for further preclinical studies, being a high potential drug to effective and safe chemotherapy to Chagas disease. | en |
dc.description.affiliation | Sao Paulo State University “Júlio de Mesquita Filho” UNESP Faculty of Pharmaceutical Sciences Department of Pharmaceuticals and Medicines, SP | |
dc.description.affiliationUnesp | Sao Paulo State University “Júlio de Mesquita Filho” UNESP Faculty of Pharmaceutical Sciences Department of Pharmaceuticals and Medicines, SP | |
dc.identifier | http://dx.doi.org/10.1590/s2175-97902022e20277 | |
dc.identifier.citation | Brazilian Journal of Pharmaceutical Sciences, v. 58. | |
dc.identifier.doi | 10.1590/s2175-97902022e20277 | |
dc.identifier.issn | 2175-9790 | |
dc.identifier.issn | 1984-8250 | |
dc.identifier.scopus | 2-s2.0-85145907565 | |
dc.identifier.uri | http://hdl.handle.net/11449/249542 | |
dc.language.iso | eng | |
dc.relation.ispartof | Brazilian Journal of Pharmaceutical Sciences | |
dc.source | Scopus | |
dc.subject | Acute stage | |
dc.subject | Benznidazole (BZN) | |
dc.subject | Bolivia strain | |
dc.subject | Chagas disease | |
dc.subject | Hydroxymethylnitrofurazone (NFOH) | |
dc.subject | Trypanosoma cruzi | |
dc.title | Hydroxymethylnitrofurazone (NFOH) decreases parasitaemia, parasitism and tissue lesion caused by infection with the Bolivia Trypanosoma cruzi type I strain in Swiss and C57BL/6 mice | en |
dc.type | Artigo | pt |
dspace.entity.type | Publication | |
relation.isDepartmentOfPublication | e214da1b-9929-4ae9-b8fd-655e9bfeda4b | |
relation.isDepartmentOfPublication.latestForDiscovery | e214da1b-9929-4ae9-b8fd-655e9bfeda4b | |
unesp.author.orcid | 0000-0002-2540-6395[1] | |
unesp.department | Fármacos e Medicamentos - FCF | pt |